Last updated: May 26, 2026
DAYTRANA (methylphenidate transdermal system) suppliers: who manufactures it, supplies raw materials, and controls distribution
Daytrana is the methylphenidate transdermal system marketed in the US under the Shire/Alliance legacy. Brand Daytrana product supply is tied to the commercial manufacturing network for the transdermal system and to controlled-substance distribution channels. The supplier set includes (1) the brand’s drug-product manufacturer(s), (2) the transdermal manufacturing subcontractors for adhesive/membrane systems, and (3) contract suppliers of methylphenidate API and excipients used in controlled-release patches.
Who are the pharmaceutical drug suppliers for Daytrana (methylphenidate transdermal system) in the US?
Daytrana suppliers break into three practical layers: drug substance (methylphenidate API), drug product (patch manufacturing), and logistics (controlled-substance distribution).
Drug product manufacturing: who makes the Daytrana patch
Daytrana is a transdermal methylphenidate product with a defined strength ladder and patch construction (backing, adhesive matrix, rate-controlling membrane where applicable, and controlled-release components). In the US, supply typically runs through one or more labeled manufacturers on the FDA label and/or on the Orange Book listing for the reference listed drug (RLD).
Supplier categories
- Licensed finished-dose manufacturer(s for “Daytrana” (patch dosage form and packaging).
- Co-manufacturers / packaging contractors that handle blistering, pouching, and unit packout aligned with controlled-substance requirements.
- Specialty transdermal formulation subcontractors (adhesive matrix and laminate processing), usually not named publicly unless they are the labeled manufacturer.
Drug substance suppliers: methylphenidate API sources
Methylphenidate is a regulated active ingredient and API supply is usually limited to qualified producers with the right regulatory track record for controlled substances. API suppliers generally change only when qualification, stability, and regulatory documentation are updated.
What to verify in listings
- Whether the Orange Book lists an NDA for Daytrana and whether it provides an ANDA/RLD connection.
- The labeled manufacturer name(s) on the Daytrana package insert (drug product manufacturing responsibility).
- Strength-specific manufacturing where the patch sizes differ.
Distribution suppliers: who moves Daytrana through the supply chain
Daytrana is a Schedule II stimulant in the US. Distribution is therefore typically handled by:
- Wholesalers with controlled-substance authorization
- Securitized logistics providers meeting DEA and state controlled-substance distribution requirements
- Returns and destruction contractors for damaged/expired product
Public “supplier” lists usually stop at the wholesaler level because the branded company typically controls wholesale distribution strategy and uses contracted logistics for last-mile and inventory management.
What patents protect Daytrana (methylphenidate transdermal system) formulation and delivery?
Daytrana’s exclusivity and generic entry risk are driven by two IP buckets: (1) core composition and (2) transdermal controlled-release delivery system design, including patch construction and rate control.
Which patent types typically matter for Daytrana
- Transdermal formulation patents (adhesive matrix composition, polymer blends, tackifier systems, drug loading).
- Rate-controlling system patents (membrane or diffusion-control layers).
- Manufacturing method patents (lamination, coating, drying/curing parameters, and quality specs linked to drug release rate).
How to use patent estate mapping for supplier decisions
Supplier qualification for a future generic or licensed patch often hinges on:
- Whether the generic patch design can avoid the controlled-release design claims.
- Whether method-of-manufacture claims constrain process options.
- Whether formulation changes are allowed without falling under design-around limitations.
What is the Orange Book status of Daytrana, and what generic patch risks exist?
Orange Book status determines whether Daytrana is still under active market exclusivity and whether ANDAs are pending.
How Orange Book listings affect “supplier” strategy
- If Daytrana’s RLD has expiring patents and no active restraints, suppliers can plan scale-up for generic patch production.
- If one or more listed patents remain unexpired, contract manufacturers may require design changes and IP clearance before investing in line modifications.
What to check for Daytrana
- The RLD name and NDA number for Daytrana
- Listed patent numbers and their expiration and Hatch-Waxman exclusivity end dates
- Whether any ANDAs are listed as “Paragraph IV” with any settlement or court outcome
(Orange Book extraction is required for a complete and accurate supplier-and-expiration mapping. Without Orange Book listing details, an exact “who-and-when” table cannot be populated.)
When does Daytrana lose exclusivity and what does that mean for patch manufacturers?
Exclusivity and patent expiration dates determine when contract manufacturers can safely:
- qualify a generic patch,
- start meaningful procurement of API and excipients,
- and ship commercial inventory without injunction risk.
Timing drivers
- Patent expiration (composition/formulation/delivery-system patents)
- Regulatory exclusivity (any remaining marketing exclusivity)
- Pediatric exclusivity (if applicable and relevant to the NDA)
- 30-month stays tied to Paragraph IV challenges (if present)
Which companies challenge Daytrana with Paragraph IV ANDAs or litigation?
Paragraph IV filers for transdermal methylphenidate products typically include patch-specialist generic developers and larger portfolio players that already support transdermal platforms.
Litigation-linked supplier implications
When there are Paragraph IV disputes, finished-dose manufacturers generally face:
- restrictions on sourcing a specific patch design that overlaps with asserted claims,
- higher QA and validation overhead,
- potential injunction-triggered inventory write-offs.
(Without specific Orange Book ANDA and litigation docket details, the exact challenger list for Daytrana cannot be stated.)
How does Daytrana compare with other methylphenidate transdermal patches for supplier landscape?
The supplier landscape differs by delivery system even when the active ingredient is the same.
Key comparative dimensions
- Patch architecture (rate control layer, adhesive strategy)
- Strength and wear-time regime (once-daily vs step-down designs)
- Bioequivalence strategy (differing patch designs can still achieve equivalent systemic exposure)
For suppliers, the main takeaway is that a transdermal platform is not fully transferable. A contract manufacturer may handle multiple patch brands, but it still requires product-specific formulation know-how.
What formulations are protected for Daytrana (methylphenidate transdermal system), and how does that affect contract manufacturing?
Transdermal protection typically targets:
- adhesive matrix composition and drug release characteristics
- rate-controlling features in the patch
- manufacturing process steps tied to controlled-release behavior
Manufacturing/IP barriers that slow patch supply
- Process parameters that change drug release rate may be constrained by IP claims.
- Changes in excipients can shift release profiles, risking both equivalence and claim overlap.
What regulatory status does Daytrana have, and how do suppliers maintain compliance?
Daytrana is regulated as a drug with controlled substance requirements in the US.
Supplier compliance requirements
- DEA and state controlled substance distribution authorization for wholesalers and handlers
- GMP compliance for patch manufacturing and packaging
- Stability and tamper-evidence controls for patch integrity
Commercial supply exposure: what drives Daytrana availability and supplier leverage?
For transdermal patches, supply constraints typically arise from:
- specialized coating/lamination capacity
- adhesive supply chain constraints
- regulatory release and stability schedule
- controlled-substance allocation practices
If Daytrana’s labeled manufacturer(s) are few, supplier leverage can increase during capacity bottlenecks.
Key takeaways
- Daytrana supplier structure has three layers: controlled-substance distribution, patch drug product manufacturing, and methylphenidate API and excipient supply.
- Supplier qualification and generic competition hinge on transdermal formulation and controlled-release design IP.
- Orange Book status and specific patent expiration timelines determine when additional patch manufacturers can enter without IP risk.
- Without the Orange Book entry details and labeled manufacturer names, a precise, named supplier roster for “who supplies Daytrana” cannot be compiled accurately.
FAQs
- Is Daytrana manufactured by the same company that supplies the methylphenidate API?
- Do Daytrana generics face the same transdermal adhesive and rate-control formulation barriers?
- How do Paragraph IV challenges change patch manufacturing and supply chain planning?
- Which controlled-substance distribution model is typically used for Schedule II patches like Daytrana?
- What packaging constraints affect patch suppliers during GMP release for controlled substances?
References (APA)
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/daf/
- FDA. Drugs@FDA database. https://www.accessdata.fda.gov/scripts/cder/daf/
- DEA. Controlled Substances Act and DEA registration requirements (general guidance). https://www.dea.gov/
